Statins and ezetimibe

Combination Therapy In Dyslipidemia

Volumn , Issue , 2015, Pages 25-36

  Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84952707881     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/9783319204338_3     Document Type: Chapter

References (36)

1. Schoenheimer R. Uber die Bedeutung der Pflanzensterine fur den tierischen Organismus. Z Phys Chem. 1929;180:1.
2. Altmann SW, Davis Jr HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201-1204.
3. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-427.
4. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943-1948.
5. Salen G, von Bergmann K, Kwiterovitch P, et al. Ezetimibe is an effective treatment for homozygous sitosterolemia. Circulation. 2002;106(suppl II):2-185.
6. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercho- lesterolaemia. Drugs. 2002;62(16):2333-2347.
7. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezeti- mibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003;107(25): 3124-3128.
8. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580.
9. Klose G, Laufs U, Marz W, Windler E. Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int. 2014;111(31-32):523-529.
10. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density Lipoprotein cholesterol beginning early in Life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25): 2631-2639.
11. Ference BA. Effect of naturally random allocation to lower LDL-C mediated by polymorphisms in NPC1L1, HMGCR or both on the risk of coronary heart disease: a 2x2 Factorial Mendelian Randomization Study. American Heart Association Scientific Sessions, Chicago; 16 Nov 2015 2014.
12. Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, et al. Myocardial Infarction Genetics Consortium I Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072-2082.
13. Weingartner O, Lutjohann D, Ji S, Weisshoff N, List F, Sudhop T, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008; 51(16): 1553-15561.
14. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezeti- mibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003; 107(19): 2409-2415.
15. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, et al. Efficacy and safety of ezeti- mibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008; 102(11): 1495-1501.
16. Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008; 62(4): 539-554.
17. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract. 2009; 63(4): 547-559.
18. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol. 2008; 102(11): 1489-1494.
19. Hurley DL, Isley WL. Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals. Mayo Clin Proc. 2005; 80(5): 587-595.
20. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14): 1431-1443.
21. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008; 52(25): 2198-2205.
22. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13): 1343-1356.
23. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
24. Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. American Heart Association Scientific Sessions, Chicago; 17 Nov 2014.
25. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015. doi:10.1056/NEJMoa1410489.
26. Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014; 168(2): 205-12.e1.
27. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008; 156(5): 826-832.
28. Packard CJ. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year followup of the West of Scotland coronary prevention study. American Heart Association Scientific Sessions, Chicago; 18 Nov 2014 2014.
29. Urban D, Poss J, Bohm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013; 62(16): 1401-1408.
30. Schulz R, Schluter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015;110(2):463.
31. Lipka L, Kerzner B, Corbelli J. Results of ezetimibe coadministered with lovastatin in 548 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(9 suppl B):430B.
32. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Ezetimibe co-administered with pravastatin in 538 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(9 suppl B):134B.
33. Davidson M, McGarry T, Bettis R, et al. Ezetimibe Study Group. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(Suppl A):226A-227A.
34. Ballantyne C, Houri J, Notarbatolo A, et al. Ezetimibe Study Group. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(Suppl A):227A.
35. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, Veltri EP. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004;58(7):653-658.
36. Laufs U, Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J. 2014; 35(30): 1996-2000.